Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Income towards Parent Company: 2021-2025

Historic Income towards Parent Company for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Sep 2025 value amounting to -$34.4 million.

  • Amylyx Pharmaceuticals' Income towards Parent Company rose 52.70% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$148.9 million, marking a year-over-year increase of 42.66%. This contributed to the annual value of -$301.4 million for FY2024, which is 714.44% down from last year.
  • Amylyx Pharmaceuticals' Income towards Parent Company amounted to -$34.4 million in Q3 2025, which was up 17.03% from -$41.4 million recorded in Q2 2025.
  • Amylyx Pharmaceuticals' Income towards Parent Company's 5-year high stood at $22.1 million during Q2 2023, with a 5-year trough of -$118.8 million in Q1 2024.
  • For the 3-year period, Amylyx Pharmaceuticals' Income towards Parent Company averaged around -$33.1 million, with its median value being -$35.9 million (2025).
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' Income towards Parent Company surged by 140.81% in 2023, and later tumbled by 7,652.00% in 2024.
  • Quarterly analysis of 5 years shows Amylyx Pharmaceuticals' Income towards Parent Company stood at -$28.3 million in 2021, then tumbled by 54.54% to -$43.8 million in 2022, then surged by 110.29% to $4.5 million in 2023, then slumped by 924.69% to -$37.2 million in 2024, then skyrocketed by 52.70% to -$34.4 million in 2025.
  • Its last three reported values are -$34.4 million in Q3 2025, -$41.4 million for Q2 2025, and -$35.9 million during Q1 2025.